Aimwell Partners Inc. reports company developments centered on AimwellBio, its healthcare and biopharmaceutical intelligence business. Recurring announcements cover the rollout of AIMWELL Cortex, the Federated Health Intelligence Network, source-traceable signal monitoring, confidence scoring, and verification processes designed for clinical, research, regulatory, and biopharma users.
Company news also describes demonstrations, onboarding activity, founding cohort development, live signal intelligence features, and engagement with clinicians, researchers, hospital systems, physician networks, and strategic advisors. The updates frame AimwellBio's work around healthcare RegTech, AI-output verification, clinical information validation, and structured intelligence mapping.
Aimwell Partners (AIMN) completed a restructuring of its legacy debt, replacing the prior fixed settlement price with a market-linked conversion price. A new, unaffiliated holder purchased the obligations from the company's majority debt holder and agreed to the revised terms. Conversion is now priced at a 45% discount to market, as determined under the amended agreement; principal and accrued interest are unchanged.
Using the October 22, 2026 closing price of $0.0013, the company illustrated approximately 98.6% fewer conversion shares than under the prior fixed price. Actual issuance depends on market prices, conversion amounts and timing, and agreement terms; falling prices mean more shares. Aimwell recently acquired intellectual property expanding AimwellBio's verification and engagement capabilities. It is in preliminary discussions with healthcare and biotech companies and intends to pursue acquisitions and collaborations.
Aimwell Partners (AIMN) expanded its AimwellBio healthcare discovery platform, adding AI visibility assessments and paid services for healthcare practices.
The website offers a free three-question scan without signup and a free twelve-question report prepared by a person and delivered by email. Paid options include a $49 Gap Report, a $149 Action Plan with a follow-up scan after thirty days, and website implementation packages starting at $499, subject to an approved scope.
The company also invited public nominations of healthcare professionals for potential features, subject to verification and editorial review. AimwellBio is evaluating additional healthcare discovery, patient engagement and virtual-care integration opportunities, subject to development, partner arrangements, applicable regulatory requirements and commercial validation.
Aimwell Partners (AIMN) has opened applications for healthcare professionals and businesses seeking to be featured on AimwellBio's healthcare intelligence network. The invitation follows inbound inquiries after its VitalCare of Shelton announcement.
AimwellBio is developing questionnaires to capture practice priorities and inform tailored intelligence. The company expects to announce additional platform features in the coming weeks. Selection will consider credentials, practice information, and alignment with the network's published methodology and standards for verified intelligence.
Aimwell Partners (AIMN) launched AimwellBio's Provider Verification Registry, a public-facing healthcare information resource whose inaugural profile covers Vital Care of Shelton.
The Connecticut infusion pharmacy's profile brings together services, ownership, referral workflows, licensure and accreditation information. Profiles combine providers' published materials with independent credential records; the Registry is editorial, not pay-for-placement. AimwellBio is developing a founding provider cohort, with publication dependent on provider cooperation and independently verifiable information. The company intends the resource to help patients assess care options and clinicians evaluate referral partners.
Aimwell Partners (AIMN), parent of AimwellBio, announced a professional visibility program for physicians and doctors of chiropractic across AI assistants and search engines.
The program offers verified, AI-indexable professional profiles, press opportunities subject to publisher standards, and free, no-obligation visibility assessments across selected platforms. AimwellBio aims to address missing, outdated or inaccurate information about practitioners. Participants must undergo identity and credential verification appropriate to their profession. The services do not guarantee indexing, rankings, placement or particular outputs from third-party systems.
Aimwell Partners (AIMN), parent of AimwellBio, announced plans on September 15, 2026 to integrate telemedicine into its verified health intelligence platform and opened applications for a ten-seat Founding Physician Cohort.
The initial cohort will consist of licensed physicians across GLP-1 and metabolic care, hormone and menopause health, and other physician-directed injectable and peptide therapies for men and women. Founding physicians will receive a verified AimwellBio profile, editorial and press visibility, membership in the Federated Health Intelligence Network, a personalized research command center, and priority access to a planned turnkey virtual-practice platform, all at no cost.
The company is evaluating national telehealth infrastructure providers to support compliant care delivery. Physician verification on AimwellBio is credential-based and not purchasable, and participating physicians will retain independent clinical judgment. Licensed physicians may apply via aimwellbio.com/founding-physicians or corporate@aimwellbio.com.
Aimwell Partners (AIMN) opened its AIMN:ATLAS global biopharma intelligence map to the public at aimwellbio.com/atlas, removing login, forms, and sales gates.
The map covers thousands of entities across eleven regulatory zones and more than 9,200 indexed signals from PubMed, FDA, ClinicalTrials.gov, and SEC EDGAR, refreshed on a schedule. The company highlights that Saudi Arabia’s SFDA currently ranks as the highest-scored regulatory zone. Following the earlier Trustr behavioral engagement IP acquisition, Dr. Chris A. Jones is building out AimwellBio’s advisory bench and has initiated discussions with multiple potential collaborators and senior physicians. Companies and credentialed professionals can contact AimwellBio directly at corporate@aimwellbio.com for collaboration, advisory roles, or platform access.
Aimwell Partners (OTCID:AIMN), through its subsidiary Aimwell Bio, has executed a definitive Intellectual Property Purchase and Assignment Agreement to acquire the Trustr behavioral engagement portfolio from its principal inventor, Dr. Christopher A. Jones. The deal transfers a patent family, source code, machine-learning models, algorithms, reward‑timing and loss‑aversion systems, trademarks, trade secrets, and technical know‑how.
According to Aimwell Partners, consideration is being paid in restricted shares of Aimwell Bio common stock, with no cash component. Dr. Jones is also introducing scientists, clinicians, and strategic contributors involved in Trustr’s development, who will be publicly named as their individual agreements are signed. The company positions Trustr as adding proprietary behavioral infrastructure to its existing “verified intelligence” RegTech platform for the medical industry.
AimwellBio (OTCID:AIMN) announced the executed assignment of the Trustr intellectual property portfolio, a patented behavioral engagement system that measures real-world patient behavior and delivers timed, data-driven interventions and rewards to support treatment adherence.
The portfolio brings a decade of work, including a 2017 University of Vermont license, review by Cornell Consulting Group, a Gold Ribbon at AMCP 2020, a Sanofi pilot in moderate-to-severe asthma, and peer‑reviewed research in the Journal of Health Economics and Outcomes Research. Inventor Dr. Chris A. Jones has joined AimwellBio’s Board of Advisors, is expanding its scientific and medical network, and the assignment structure includes provisions recognizing original Trustr shareholders.
AimwellBio (OTC:AIMN) has published a confidential investor briefing on the recently acquired Trustr behavioral engagement intellectual property portfolio, which the company values at $10 million. The U.S. patent family covers systems that measure real-world behavior against personalized performance indicators and deliver timed reward and loss-aversion messages to support sustained behavioral change.
According to AimwellBio, the technology has institutional lineage involving the University of Vermont, Cornell Consulting Group, AMCP recognition, and a Sanofi asthma pilot. Inventor Dr. Chris A. Jones has joined AimwellBio's Board of Advisors to lead further platform expansion and additional IP evaluation. The briefing also outlines remaining diligence items and is available to current and prospective investors upon request.